Tenofovir/probenecid combination in HIV/HBV-coinfected patients: How to escape Fanconi syndrome recurrence?

AIDS

Volumn 24, Issue 7, 2010, Pages 1078-1079

  Izzedine, Hassane ^a   Thibault, Vincent ^b   Valantin, Marc Antoine ^a   Peytavin, Gilles ^c   Schneider, Luminita ^a   Benhamou, Yves ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b Virology Laboratory   (France)

^c BICHAT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ENTECAVIR; LAMIVUDINE; PROBENECID; TENOFOVIR; TENOFOVIR DISOPROXIL;

DRUG BLOOD LEVEL; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FANCONI RENOTUBULAR SYNDROME; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY INJURY; LETTER; MIXED INFECTION; NEPHROTOXICITY; PRIORITY JOURNAL; RECURRENT DISEASE; VIRUS LOAD;

ADENINE; FANCONI SYNDROME; HEPATITIS B, CHRONIC; HIV INFECTIONS; HIV-1; HUMANS; MALE; PHOSPHONIC ACIDS; PROBENECID; RECURRENCE;

EID: 77950939762     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3283313f54     Document Type: Letter

References (4)

1. Cundy KC, Sueoka C, Lynch GR, Griffin L, Lee WA, Shaw JP. Pharmacokinetics and bioavailability of the antihuman immunodeficiency virus nucleotide analog 9-[(R)-2-(phosphono-methoxy)propyl]adenine (PMPA) in dogs. Antimicrob Agents Chemother 1998; 42:687-690.
2. Benhamou Y, Bochet M, Thibault V, Calvez V, Fievet MH, Vig P, et al. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. Lancet 2001; 358:718-723.
3. Uwai Y, Ida H, Tsuji Y, Katsura T, Inui K. Renal transport of adefovir, cidofovir, and tenofovir by SLC22A family members (hOAT1, hOAT3, and hOCT2). Pharm Res 2007; 24:811-815.
4. Lacy SA, Hitchcock MJ, Lee WA, Tellier P, Cundy KC. Effect of oral probenecid coadministration on the chronic toxicity and pharmacokinetics of intravenous cidofovir in cynomolgus monkeys. Toxicol Sci 1998; 44:97-106